share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  08/15 21:27

牛牛AI助理已提取核心訊息

On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer...Show More
On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer satisfaction, with expectations for continued growth in the latter half of the year. MangoRx is also preparing to launch new products, including compounded oral dissolvable tablet (ODT) GLP-1 inhibitors for weight loss and a hormone therapy product for low testosterone. The company's telemedicine platform facilitates the prescription and delivery of its products directly to consumers.
2024年8月15日,Mangoceuticals公司,也被稱爲MangoRx,報告了2024年上半年其財務業績的顯著增長。該公司專注於男性健康和保健產品,包括治療勃起功能障礙、促進脫髮、減肥和激素替代療法,披露股東權益增長1685%,同比營業收入增長56%。股東權益激增至1380萬美元,較上一年末的774,754美元增加,這主要歸因於從Intramont Technologies收購了一項專利組合。截至2024年6月30日的六個月內,營業收入達到377,258美元,毛利潤爲217,190美元,相比前一年同期有明顯增長。首席執行官Jacob Cohen強調了公司的創新和客戶滿意度,預計在下半年將繼續增長。MangoRx也正在準備推出新產品,包括用於減肥的複合口服可溶片(ODT)GLP-1抑制劑和治療低睾酮的激素療法產品。該公司的遠程醫療平台可直接爲消費者開具處方並提供產品配送服務。
2024年8月15日,Mangoceuticals公司,也被稱爲MangoRx,報告了2024年上半年其財務業績的顯著增長。該公司專注於男性健康和保健產品,包括治療勃起功能障礙、促進脫髮、減肥和激素替代療法,披露股東權益增長1685%,同比營業收入增長56%。股東權益激增至1380萬美元,較上一年末的774,754美元增加,這主要歸因於從Intramont Technologies收購了一項專利組合。截至2024年6月30日的六個月內,營業收入達到377,258美元,毛利潤爲217,190美元,相比前一年同期有明顯增長。首席執行官Jacob Cohen強調了公司的創新和客戶滿意度,預計在下半年將繼續增長。MangoRx也正在準備推出新產品,包括用於減肥的複合口服可溶片(ODT)GLP-1抑制劑和治療低睾酮的激素療法產品。該公司的遠程醫療平台可直接爲消費者開具處方並提供產品配送服務。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。